An FDA panel has voted 12-1 against expanded use of Amgen's (AMGN -1.2%) Xgeva for prostate...

|About: Amgen Inc. (AMGN)|By:, SA News Editor

An FDA panel has voted 12-1 against expanded use of Amgen's (AMGN -1.2%) Xgeva for prostate cancer bone met prevention, according to a Bloomberg report. (pdf)